Antioxidant and inflammatory status of Tunisian patients with chronic spontaneous urticaria and effect of De-sloratadine: a case-control study



Objective: The aim of our study is to investigate the antioxidant status, inflammatory parameters, hematologic markers, clinical data of CSU Tunisian patients and the effect of a first-line treatment of CSU, which is Desloratadine 5mg/day on these different parameters.

Methods: This study enrolled 30 CSU patients and 30 controls. We assessed antioxidant parameters (Total antioxidant status (TAS) and glutathione S-Transferase (GST)), inflammatory markers (Albumin, Alpha 1, alpha2, beta1 globulins and CRP) and hematologic numeration. We assessed the Urticaria Activity Score (UAS).

 Results: Alpha1, alpha2, beta 1 globulins, CRP, Leucocytes and basophils were significantly increased in patients at baseline versus controls (p<0.05). TAS, GST activity and albumin were significantly decreased in patients at baseline versus controls (p<0.05). TAS and GST activity were significantly increased in patients after treatment versus patients before treatment (p<0.001). Alpha1, alpha2, beta 1 globulins, CRP, albumin, leucocytes and basophils were significantly decreased in patients after treatment versus patients before treatment (p<0.05). A significant correlation between CRP and UAS (r=0.2; p<0.001) was noted. UAS assessment highlighted the efficacy of 30 days-antihistaminic treatment.

 Conclusion: Our study emphasizes the involvement of oxidative stress in CSU. Interestingly, we found that desloratadine exerted anti-inflammatory and antioxidant effects.

Full Text:



Kolkhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites - a systematic review. Aller-gy. 2015.

Fernando S, Broadfoot A. Chronic urticaria--assessment and treatment. Aust Fam Physician .2010; 39(3): 135-8.

Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 2003; 3: 363-368.

Negro-Alvarez JM, Miralles-Lopez JC. Chron-ic idiopathic urticaria treatment. Allergol Im-munopathol. 2001; 29: 129-132.

Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treat-ment of chronic idiopathic urticaria: a ran-domized, double-blind, placebo-controlled study. Br J Dermatol. 2006; 154: 533–538.

Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D et al. Clinical and laboratory parameters in predicting chronic urticaria du-ration: a prospective study of 139 patients. Al-lergy. 2004; 59(8): 869-73.

Naaman S, Sussman G. Chronic idiopathic ur-ticaria: treatment with omalizumab. Skin Ther-apy Lett. 2014; 19(6): 1-4.

Braconi D, Bernardini G, Santucci A. Post-genomics and skin inflammation. Mediators Inflamm. 2010; 2010: 364823.

Briganti S, Picardo M. Antioxidant activity, li-pid peroxidation and skin diseases. What’s new. J Eur Acad Dermatol Venereol. 2003; 17: 663-9.

Yalcin AD. Advances in Anti-IgE Therapy. Bi-omed Res Int. 2015; 2015 :317465.

Jain S. Pathogenesis of Chronic Urticaria: An Overview. Dermatol Res Prat. 2014 (2014); 10-20.

Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001; 10: 751–762.

Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idio-pathic urticaria: a double-blind, randomised, placebo-controlled trial. J Am Acad Dermatol. 2003; 48: 535–541.

Sadowska-Woda I, Sychta B, Rachel M, Bieszczad-Bedrejczuk E. Protective effect of desloratadine against oxidative stress in hu-man erythrocytes in vitro. Environ Toxicol Pharmacol. 2010; 30(2): 141-6.

Zuberbier T, Asero R, Bindslev-Jensen C, Wal-ter Canonica G, Church MK, Giménez-Arnau A et al. EAACI/GA(2)LEN/EDF/WAO guide-line: definition, classification and diagnosis of urticaria. Allergy. 2009; 64(10):1417-26.

Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974; 249: 7130-7139.

Fukuda S, Shimoyama T, Umegaki N, Mikami T, Nakano H, Munakata A. Effect of Helico-bacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urti-caria. J Gastroenterol. 2004; 39(9): 827-30.

Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urti-caria. Cochrane Database Syst Rev. 2014; 11: CD006137.

Wu KC, Jabbar-Lopez ZK. Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria. J Invest Dermatol. 2015; 135: 13–15.

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; 69(7): 868-87.

Kasperska-Zajac A, Brzoza Z, Polaniak R, Ro-gala B, Birkner E. Markers of antioxidant de-fence system and lipid peroxidation in periph-eral blood of female patients with chronic idi-opathic urticaria. Arch Dermatol Res. 2007; 298(10): 499-503.

Sagdic A, Sener O, Bulucu F, Karadurmus N, Yamanel L, Tasci C et al. Oxidative stress sta-tus in patients with chronic idiopathic urticar-ia. Allergol Immunopathol (Madr). 2011; 39(3): 150-3.

Cassano N, Raho G, Filieri M, D’Argento V, Amoruso A, Filotico R et al. Influence of de-sloratadine on oxidative stress markers in pa-tients with chronic idiopathic urticaria. Int J Dermatol. 2006; 45: 394-6.

Ohtsuka T. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticarial. Int J Dermatol. 2010; 49(5): 579-84.

Takahagi S, Mihara S, Iwamoto K, Morioke S, Okabe T, Kameyoshi Y et al. Coagulation / fibrinolysis and inflammation markers are as-sociated with disease activity in patients with chronic urticaria. Allergy. 2010; 65(5): 649-56.

Grzanka A, Damasiewicz-Bodzek A, Machura E, Szumska M, Tyrpień-Golder K, Mazur B et al. Chronic Spontaneous Urticaria Is Char-acterized by Lower Serum Advanced Gly-cation end-products. Biomed Res Int. 2014; 2014: 974154.

Kasperska-Zajac A. Acute-phase response in chronic urticaria. J Eur Acad Dermatol Vene-reol. 2012; 26: 665-72.

Kasperska-Zając A, Grzanka A, Jarzab J, Mis-iołek M, Wyszyńska-Chłap M, Kasperski J et al. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int. 2014; 2014: 650913.


  • There are currently no refbacks.